Explore the reality of schizophrenia by debunking seven myths and offering compassionate insights into this complex mental ...

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Events like one held Thursday at Fayetteville Town Center can affect how challenges surrounding schizophrenia and mental ...

Using a multi-strain probiotic formulation, researchers conducted a double-blind, randomized, placebo-controlled trial aimed at improving psychiatric and cognitive symptoms, intestinal permeability, ...

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

treatment, and general understanding of schizophrenia, remains to be determined. It may be useful, however, for both clinicians and researchers to be aware of this phenomenon and to incorporate ...

Today, in 2025, I remember my four years homeless in Los Angeles, and am thankful for my recovery from schizophrenia.

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

We propose that there are existing treatments for the alleviation of negative symptoms, which may provide a novel treatment for patients with comorbid schizophrenia and cocaine abuse.